Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3Classical hematology 1

Conditions

Thrombocytopenia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Prolymphocytic 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Blast Crisis 1Anemia, Refractory, with Excess of Blasts 1Anemia 1

Interventions

fludarabine phosphate 22Cyclophosphamide 20Busulfan 20Peripheral Blood Stem Cell Transplantation 16Cyclosporine 16Filgrastim 13Antilymphocyte Serum 13Mycophenolic Acid 11Melphalan 11Radiotherapy 10Methotrexate 10Cytarabine 10Methylprednisolone 9Cord Blood Stem Cell Transplantation 9Whole-Body Irradiation 8Tacrolimus 8Etoposide 8Granulocyte Colony-Stimulating Factor 5fludarabine 4Thiotepa 4Sirolimus 4Carboplatin 4Topotecan 3Leucovorin 3lintuzumab 2Vorinostat 2Tretinoin 2Therapeutics 2Immunoenzyme Techniques 2Idarubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Blast Crisis × alvocidib × Classical hematology × Clear all
NCT00278330 2013-04-02

Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia

National Cancer Institute (NCI)

Phase 1 Completed
24 enrolled
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Blast Crisis, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡